Summary & Overview
HCPCS J0606: Injection, etelcalcetide, 0.1 mg
HCPCS Level II code J0606 denotes the injectable medication etelcalcetide at 0.1 mg per unit. Etelcalcetide is a calcimimetic agent administered parenterally, commonly used in the management of secondary hyperparathyroidism in patients receiving hemodialysis. Nationally, this code is relevant for outpatient dialysis centers, hospital outpatient departments, and clinics that provide intravenous therapies to patients with chronic kidney disease.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of etelcalcetide, typical sites of service, and operational billing considerations tied to HCPCS Level II code J0606. The publication outlines available benchmarking information where present, summarizes applicable policy updates affecting coverage and coding, and highlights common billing themes and documentation priorities related to parenteral calcimimetic therapy.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes is noted where applicable.
Billing Code Overview
HCPCS Level II code J0606 represents an injection of etelcalcetide, 0.1 mg. This billing code describes a parenteral pharmaceutical administration used in medical management where an injectable calcimimetic agent is required.
-
Service type: Intravenous or intramuscular pharmaceutical injection
-
Typical site of service: Outpatient infusion or dialysis center, hospital outpatient department, or clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving J0606 (injection, etelcalcetide, 0.1 mg) is an adult with end-stage renal disease (ESRD) on maintenance hemodialysis who has persistent secondary hyperparathyroidism despite oral therapy. The patient presents to an outpatient dialysis center for a scheduled hemodialysis session. During pre-dialysis assessment the nephrology nurse documents elevated intact parathyroid hormone (iPTH) and hypercalcemia or hyperphosphatemia not adequately controlled with oral cinacalcet or vitamin D analogs. The dialysis provider orders intravenous etelcalcetide to be administered at the end of the hemodialysis treatment.
The clinical workflow includes verification of the physician order and dose, review of recent laboratory values (calcium, phosphorus, iPTH), medication reconciliation, and informed consent as per facility policy. Pharmacy prepares the etelcalcetide vial or syringe per manufacturer instructions and facility sterile handling protocols. The dialysis nurse administers J0606 intravenously via the dialysis venous line at the end of treatment, documents lot number and dose in the medication administration record, monitors for immediate adverse reactions (hypocalcemia, muscle cramps, paresthesia), and schedules follow-up labs and nephrology review. Billing staff link the drug administration to the patient’s dialysis session and apply appropriate modifier(s) as required by the payer for medical necessity, site of service, or billing rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|